## Bodo B Beck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7418061/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The primary hyperoxalurias. Kidney International, 2009, 75, 1264-1271.	5.2	314
2	ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. Journal of Clinical Investigation, 2013, 123, 3243-3253.	8.2	196
3	Polyhydramnios, Transient Antenatal Bartter's Syndrome, and <i>MAGED2</i> Mutations. New England Journal of Medicine, 2016, 374, 1853-1863.	27.0	148
4	Vitamin B6 in Primary Hyperoxaluria I. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 468-477.	4.5	110
5	Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney International, 2014, 86, 1197-1204.	5.2	103
6	Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid–Resistant Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 245-253.	4.5	103
7	A molecular mechanism explaining albuminuria in kidney disease. Nature Metabolism, 2020, 2, 461-474.	11.9	99
8	Renal fibrosis is the common feature of autosomal dominant tubulointerstitial kidney diseases caused by mutations in mucin 1 or uromodulin. Kidney International, 2014, 86, 589-599.	5.2	86
9	C3 deposition glomerulopathy due to a functional Factor H defect. Kidney International, 2009, 75, 1230-1234.	5.2	79
10	Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatric Nephrology, 2017, 32, 733-741.	1.7	76
11	Whole exome sequencing identifies causative mutations in the majority of consanguineous or familial cases with childhood-onset increased renal echogenicity. Kidney International, 2016, 89, 468-475.	5.2	74
12	Germline De Novo Mutations in ATP1A1 Cause Renal Hypomagnesemia, Refractory Seizures, and Intellectual Disability. American Journal of Human Genetics, 2018, 103, 808-816.	6.2	74
13	Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. European Journal of Human Genetics, 2013, 21, 162-172.	2.8	71
14	Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opinion on Investigational Drugs, 2013, 22, 117-129.	4.1	61
15	Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney International, 2019, 96, 1389-1399.	5.2	61
16	Single-nephron proteomes connect morphology and function in proteinuric kidney disease. Kidney International, 2018, 93, 1308-1319.	5.2	49
17	Liver cell transplantation in severe infantile oxalosisa potential bridging procedure to orthotopic liver transplantation?. Nephrology Dialysis Transplantation, 2012, 27, 2984-2989.	0.7	43
18	Single molecule real time sequencing in ADTKD-MUC1 allows complete assembly of the VNTR and exact positioning of causative mutations. Scientific Reports, 2018, 8, 4170.	3.3	40

BODO B BECK

#	Article	IF	CITATIONS
19	Mucin-1 Increases Renal TRPV5 Activity In Vitro, and Urinary Level Associates with Calcium Nephrolithiasis in Patients. Journal of the American Society of Nephrology: JASN, 2016, 27, 3447-3458.	6.1	38
20	Noninvasive Immunohistochemical Diagnosis and Novel MUC1 Mutations Causing Autosomal Dominant Tubulointerstitial Kidney Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 2418-2431.	6.1	38
21	Refining genotype–phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants. Kidney International, 2021, 100, 650-659.	5.2	38
22	Three-layered proteomic characterization of a novel <i>ACTN4</i> mutation unravels its pathogenic potential in FSGS. Human Molecular Genetics, 2016, 25, 1152-1164.	2.9	36
23	An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes. Kidney International, 2020, 98, 1589-1604.	5.2	27
24	Autosomal Dominant Mutation in the Signal Peptide of Renin in a Kindred With Anemia, Hyperuricemia, and CKD. American Journal of Kidney Diseases, 2011, 58, 821-825.	1.9	26
25	A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney International, 2021, 100, 621-635.	5.2	26
26	Biallelic Expression of Mucin-1 in Autosomal Dominant Tubulointerstitial Kidney Disease: Implications for Nongenetic Disease Recognition. Journal of the American Society of Nephrology: JASN, 2018, 29, 2298-2309.	6.1	25
27	mTOR-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 2885-2899.	6.1	24
28	Systematic assessment of urinary hydroxy-oxo-glutarate for diagnosis and follow-up of primary hyperoxaluria type III. Pediatric Nephrology, 2017, 32, 2263-2271.	1.7	22
29	A de novo <b><i>KCNA1</i></b> Mutation in a Patient with Tetany and Hypomagnesemia. Nephron, 2018, 139, 359-366.	1.8	22
30	Lifelong effect of therapy in young patients with the <i>COL4A5</i> Alport missense variant p.(Gly624Asp): a prospective cohort study. Nephrology Dialysis Transplantation, 2022, 37, 2496-2504.	0.7	16
31	De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis. American Journal of Human Genetics, 2021, 108, 357-367.	6.2	14
32	Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer. BMC Medical Genetics, 2017, 18, 53.	2.1	13
33	Autosomal Tubulointerstitial Kidney Disease—MUC1 Type: Differential Proteomics Suggests that Mutated MUC1 (insC) Affects Vesicular Transport in Renal Epithelial Cells. Proteomics, 2018, 18, e1700456.	2.2	13
34	Inhomogeneous Longitudinal Cardiac Rotation and Impaired Left Ventricular Longitudinal Strain in Children and Young Adults with End‧tage Renal Failure Undergoing Hemodialysis. Echocardiography, 2015, 32, 1250-1260.	0.9	11
35	Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study. Pediatric Nephrology, 2019, 34, 2591-2600.	1.7	11
36	Hypomagnesemia is underestimated in children with HNF1B mutations. Pediatric Nephrology, 2020, 35, 1877-1886.	1.7	11

BODO B BECK

#	Article	IF	CITATIONS
37	Diverse molecular causes of unsolved autosomal dominant tubulointerstitial kidney diseases. Kidney International, 2022, 102, 405-420.	5.2	10
38	Familial juvenile hyperuricemic nephropathy as rare cause of dialysis-dependent chronic kidney disease—a series of cases in two families. Renal Failure, 2016, 38, 1759-1762.	2.1	9
39	Expanding the Spectrum of FAT1 Nephropathies by Novel Mutations That Affect Hippo Signaling. Kidney International Reports, 2021, 6, 1368-1378.	0.8	7
40	Hyperuricemia Is an Early and Relatively Common Feature in Children with HNF1B Nephropathy but Its Utility as a Predictor of the Disease Is Limited. Journal of Clinical Medicine, 2021, 10, 3265.	2.4	7
41	A step towards precision medicine in management of severe transient polyhydramnios: <i>MAGED2</i> variant. Journal of Obstetrics and Gynaecology, 2019, 39, 395-397.	0.9	6
42	NPHP1 gene-associated nephronophthisis is associated with an occult retinopathy. Kidney International, 2021, 100, 1092-1100.	5.2	6
43	Four Cases of Maturity Onset Diabetes of the Young (MODY) Type 5 Associated with Mutations in the Hepatocyte Nuclear Factor 1 Beta (HNF1B) Gene Presenting in a 13-Year-Old Boy and in Adult Men Aged 33, 34, and 35 Years in Poland. American Journal of Case Reports, 2021, 22, e928994.	0.8	6
44	Consensus draft of the native mouse podocyte-ome. American Journal of Physiology - Renal Physiology, 2022, 323, F182-F197.	2.7	6
45	A new era of treatment for primary hyperoxaluria type 1. Nature Reviews Nephrology, 2021, 17, 573-574.	9.6	5
46	Unraveling Structural Rearrangements of the CFH Gene Cluster in Atypical Hemolytic Uremic Syndrome Patients Using Molecular Combing and Long-Fragment Targeted Sequencing. Journal of Molecular Diagnostics, 2022, 24, 619-631.	2.8	5
47	Steroid-resistentes nephrotisches Syndrom. Medizinische Genetik, 2018, 30, 410-421.	0.2	3
48	Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122* mutations in the AGXT gene Stem Cell Research, 2019, 41, 101626.	0.7	3
49	Case Report: Exome Sequencing Reveals LRBA Deficiency in a Patient With End-Stage Renal Disease. Frontiers in Pediatrics, 2020, 8, 42.	1.9	2
50	MO043HYPERURICEMIA IS RELATIVELY COMMON IN CHILDREN WITH HNF1B MUTATION, BUT ITS UTILITY AS A CLINICALLY USEFUL MARKER FOR PREDICTING THE MUTATION IS LIMITED. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	2
51	Clinical profile of a Polish cohort of children and young adults with cystinuria. Renal Failure, 2021, 43, 62-70.	2.1	2
52	MAGED2 controls vasopressin-induced aquaporin-2 expression in collecting duct cells. Journal of Proteomics, 2022, 252, 104424.	2.4	1
53	Primary hyperoxaluria – An update. Journal of Pediatric Biochemistry, 2015, 04, 101-110.	0.2	0
54	Einführung zum Thema: Erbliche Nierenerkrankungen. Medizinische Genetik, 2018, 30, 389-390.	0.2	0

#	Article	IF	CITATIONS
55	Genetische Nierensteinerkrankungen. Medizinische Genetik, 2018, 30, 438-447.	0.2	0
56	Arterial Hypertension in a 10-Year-Old Girl. American Journal of Kidney Diseases, 2021, 77, A11-A13.	1.9	0